American Academy of Ophthalmology

In a pooled subcohort analysis of YOSEMITE and RHINE, faricimab showed comparable vision outcomes with fewer injections than aflibercept in DME eyes with baseline BCVA of ≤ 20/50.

Presented at AAO 2023, a retrospective study found no statistically significant difference in retinopathy worsening between GLP-1 RAs and SGLT2 inhibitors.

Durga S. Borkar, MD, MMCi, presented her study at AAO 2023 which found trial eligibility discriminates against race/ethnicity.

Six-month RIPPLE-1 results show treatment with the IBE-814 intravitreal implant led to CST reduction and BCVA improvement in patients with DME or RVO.

In the PULSAR study, White and Asian participants had similar best corrected visual acuity improvements in the 2 mg aflibercept group.

Presented at AAO 2023, Russell Van Gelder, MD, PhD, discussed Abacus study and how KIO-301 targets low vision and end stage retinitis pigmentosa with visual acuity of light perception.

Two studies presented at AAO demonstrate that low dose atropine is associated with slowing myopia progression, but another study finds that this is not true. Thus, there are mixed results on this relationship.

Presented at AAO 2023, first-time results suggest home OCT may have a significant effect on treatment burden in the management of nAMD.

First-year results from ALTITUDE suggest RGX-314 was well-tolerated and provided meaningful improvements in disease severity at dose levels 1 and 2.

Patients who are female, in minority groups (particularly, Black or Asian), a visual acuity outside of the <20/40 to 20/200 range, and who are >70 years old receive less treatment.

Presented at AAO 2023, new 3-year data from the GALE extension study shows increasing treatment effects over time with pegcetacoplan injection for geographic atrophy.

Aflibercept 8 mg treatment did well with maintaining patients, according to a presentation focusing on the PULSAR study.

In a presentation at AAO 2023, Tsang discussed topline data from the phase 2 trial on MCO-010 optogenetic therapy for vision loss in Stargardt Disease.

ARCHER study demonstrated that the antibody ANX007 was time and dose dependent, robust, and not dependent on lesion growth.

Results from the phase 2/3 DIAMOND trial show a significant reduction in central macular thickness and significant visual gain in eyes treated with OCS-01 drops versus sham.

New, 2-year results from the phase 3 PHOTON study show continued benefit for patients with diabetic macular edema treated with aflibercept 8mg.

Without treatment, lesions > 500 µm away from the fovea will take anywhere from 3.07 years to 12.9 years to reach it. With pegcetacoplan treatment, the lesion will reach the fovea anywhere between 3.56 years – 15 years for monthly treatment and 3.47-14.6 years for treatment every other month.

Despite recommendations to consult with ophthalmologists prior to initiating semaglutide, the cardiometabolic drug was not found to be linked to worsened DR outcomes.

New AAO 2023 data suggests drugs like dapagliflozin and empagliflozin may provide greater protection against glaucoma than GLP-1 agonists or DDP-4 inhibitors.

New data from the Cleveland Clinic Cole Eye Institute showed patients not responding to anti-VEGF inhibitors could improve clinical and regimen parameters with short-term faricimab.

ChatGPT, Google Bard, and Bing Chat struggle with recommending practicing nearby ophthalmologists and disproportionate against females.

The post hoc analysis of the phase 3 YOSEMITE/RHINE trials may support the therapeutic role of dual Ang-2/VEGF-A inhibition with faricimab for DME.

For people with geographic atrophy, taking pegcetacoplan every other month (the EOM treatment) is more cost-effective than taking the medication every month (the EM treatment).

In the study from AAO 2023, patients with neovascular AMD who are on aflibercept injection treatment continued their treatments >12 weeks or 16 weeks.

A post hoc analysis of the phase 3 YOSEMITE and RHINE trials found significantly more patients had leakage resolution with faricmab than with aflibercept at Week 16.

Results from the phase 3 YOSEMITE and RHINE trials show more than half of faricimab treat-and-extend patients met the criteria for a potential every-20-week dosing extension.

The SpyGlass IOL platform showcased a 45% drop in mean intraocular pressure at 3 months in first-in-human glaucoma trial.

Safety data of the bioerodible sustained delivery intravitreal anti-VEGF treatment indicate no ocular or systemic serious adverse events with mild adverse events.

A discussion into safety data from the Phase 3 DERBY and OAKS trials on pegcetacoplan with Dr. Boyer at AAO 2022.

New data from AAO 2022 show how technology may refine a currently inefficient enrollment practice for retina disease assessment.